

Iconovo AB (publ) reintroduces liquidity provider agreement with Pareto Securities AB

Iconovo AB (publ) has decided to reintroduce a liquidity provider arrangement for trading in the company's shares and has appointed Pareto Securities AB as liquidity provider. The agreement has been entered into on more favourable commercial terms for Iconovo than the company's previous arrangement.

The purpose of the liquidity provider arrangement is to promote liquidity in the trading of the company's shares, reduce share price volatility and facilitate trading. The company had previously assessed that liquidity in its shares was satisfactory and that the need for a liquidity provider was therefore limited. However, following a reassessment of that decision, the company has decided to promptly reinstate the service through a new provider.

Pareto Securities AB will commence its assignment as liquidity provider on 6 July 2026.

Contacts

Anders Månsson, CEO

+46 76 518 8491

anders.mansson@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort®. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Tapper Partners AB.

Attachments

[Iconovo AB \(publ\) reintroduces liquidity provider agreement with Pareto Securities AB](#)